931 related articles for article (PubMed ID: 25114022)
1. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
4. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
5. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.
Trovo M; Furlan C; Polesel J; Fiorica F; Arcangeli S; Giaj-Levra N; Alongi F; Del Conte A; Militello L; Muraro E; Martorelli D; Spazzapan S; Berretta M
Radiother Oncol; 2018 Jan; 126(1):177-180. PubMed ID: 28943046
[TBL] [Abstract][Full Text] [Related]
6. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
9. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma.
Liu Q; Zhu Z; Chen Y; Deng J; Ai D; Liu Q; Wang S; Wu S; Chen J; Zhao K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):707-715. PubMed ID: 32417405
[TBL] [Abstract][Full Text] [Related]
12. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT.
Hörner-Rieber J; Bernhardt D; Blanck O; Duma M; Eich HT; Gerum S; Gkika E; Hass P; Henkenberens C; Herold HU; Hildebrandt G; Imhoff D; Kahl H; Janssen S; Jurianz K; Krempien R; Lautenschläger SF; Lohaus F; Mueller AC; Petersen C; Sackerer I; Scafa D; Schrade E; Uhlmann L; Wittig A; Guckenberger M
Clin Lung Cancer; 2019 Nov; 20(6):e667-e677. PubMed ID: 31327644
[TBL] [Abstract][Full Text] [Related]
13. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ; Yang JT; Shaverdian N; Patel J; Shepherd AF; Eng J; Guttmann D; Yeh R; Gelblum DY; Namakydoust A; Preeshagul I; Modi S; Seidman A; Traina T; Drullinsky P; Flynn J; Zhang Z; Rimner A; Gillespie EF; Gomez DR; Lee NY; Berger M; Robson ME; Reis-Filho JS; Riaz N; Rudin CM; Powell SN;
Lancet; 2024 Jan; 403(10422):171-182. PubMed ID: 38104577
[TBL] [Abstract][Full Text] [Related]
14. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.
Yeung R; Hamm J; Liu M; Schellenberg D
Radiat Oncol; 2017 Jun; 12(1):105. PubMed ID: 28637480
[TBL] [Abstract][Full Text] [Related]
15. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Petty WJ; Urbanic JJ; Ahmed T; Hughes R; Levine B; Rusthoven K; Papagikos M; Ruiz JR; Lally BE; Chan M; Clark H; D'Agostino RB; Blackstock AW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):527-535. PubMed ID: 30003996
[TBL] [Abstract][Full Text] [Related]
17. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
Decaestecker K; De Meerleer G; Lambert B; Delrue L; Fonteyne V; Claeys T; De Vos F; Huysse W; Hautekiet A; Maes G; Ost P
Radiat Oncol; 2014 Jun; 9():135. PubMed ID: 24920079
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
19. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
Han J; Song Q; Guo F; Du R; Fang H; Kang J; Lu Z
Nucl Med Commun; 2022 Jun; 43(6):717-724. PubMed ID: 35354781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
